治疗相关小细胞神经内分泌前列腺癌的临床与基因组特征:多机构前瞻性研究
活检可评估率为79%,治疗相关小细胞神经内分泌前列腺癌(t-SCNC)总体检出率为17%。
要点
- t-SCNC在mCRPC中检出率17%,与既往AR靶向治疗后生存缩短相关。
- t-SCNC中AR扩增和蛋白表达分别占67%和75%。
核心结论
- t-SCNC存在于近五分之一的mCRPC患者中,并与生存缩短相关。
- t-SCNC与DNA修复改变几乎互斥,可能为mCRPC的独特亚群。
- 转录谱分析有助于识别t-SCNC及新治疗靶点。
研究设计与样本
- 多机构前瞻性研究,纳入202例进展性mCRPC患者,接受转移灶活检并随访生存。
- 转移灶活检标本行独立盲法病理审查及RNA/DNA测序。
主要发现
- t-SCNC总体检出率为17%;t-SCNC活检标本中AR扩增和蛋白表达分别占67%和75%。
- t-SCNC在骨、淋巴结和内脏器官活检标本中检出比例相似。
- 既往接受AR靶向治疗的mCRPC患者中,t-SCNC检出与总生存缩短相关(HR 2.02;95%CI 1.07-3.82)。
关键数值与推荐
- 无监督转录组层次聚类识别出小细胞样簇,进一步富集不良生存结局(HR 3.00;95%CI 1.25-7.19)。
- t-SCNC转录特征在多个外部数据集中验证,准确率>90%。
- 鉴定出多个t-SCNC转录调节因子,包括胰腺神经内分泌标志物PDX1。
临床怎么用
- 对mCRPC患者可考虑转移灶活检以识别t-SCNC。
- t-SCNC检出提示预后不良,尤其既往接受AR靶向治疗者。
- 转录谱分析可用于t-SCNC识别及探索新治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)-targeting therapy. We sought to characterize the clinical and genomic features of t-SCNC in a multi-institutional prospective study. Methods Patients with progressive, metastatic castration-resistant prostate cancer (mCRPC) underwent metastatic tumor biopsy and were followed for survival. Metastatic biopsy specimens underwent independent, blinded pathology review along with RNA/DNA sequencing. Results A total of 202 consecutive patients were enrolled. One hundred forty-eight (73%) had prior disease progression on abiraterone and/or enzalutamide. The biopsy evaluable rate was 79%. The overall incidence of t-SCNC detection was 17%. AR amplification and protein expression were present in 67% and 75%, respectively, of t-SCNC biopsy specimens. t-SCNC was detected at similar proportions in bone, node, and visceral organ biopsy specimens. Genomic alterations in the DNA repair pathway were nearly mutually exclusive with t-SCNC differentiation ( P = .035). Detection of t-SCNC was associated with shortened overall survival among patients with prior AR-targeting therapy for mCRPC (hazard ratio, 2.02; 95% CI, 1.07 to 3.82). Unsupervised hierarchical clustering of the transcriptome identified a small-cell-like cluster that further enriched for adverse survival outcomes (hazard ratio, 3.00; 95% CI, 1.25 to 7.19). A t-SCNC transcriptional signature was developed and validated in multiple external data sets with > 90% accuracy. Multiple transcriptional regulators of t-SCNC were identified, including the pancreatic neuroendocrine marker PDX1. Conclusion t-SCNC is present in nearly one fifth of patients with mCRPC and is associated with shortened survival. The near-mutual exclusivity with DNA repair alterations suggests t-SCNC may be a distinct subset of mCRPC. Transcriptional profiling facilitates the identification of t-SCNC and novel therapeutic targets.
引用
- Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018. PMID: 29985747. doi:10.1200/JCO.2017.77.6880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。